Stocks · Health care · Pharmaceutical Preparations

Enliven Therapeutics, Inc.

ELVN Clue Score23

United States Fiscal year ends December CIK 0001672619 Results filed 5 Nov 2026

Add to watchlist

What the insiders did Net selling

Individual transactions

Insider

Date

Role

Action

Price

Amount

Lori Anne Kunkel

30 Oct 2026

Director

Exercised, kept

7,300

$18.30

$133.59K

Lori Anne Kunkel

30 Oct 2026

Director

Exercised, kept

3,741

$1.12

$4.19K

Benjamin Hohl

22 Dec 2025

Chief Financial Officer

Exercised, kept

13,000

$2.48

$32.24K

Lori Anne Kunkel

17 Dec 2025

Director

Exercised, kept

15,958

$1.12

$17.87K

Benjamin Hohl

4 Mar 2025

Chief Financial Officer

Exercised, kept

10,000

$2.48

$24.80K

Benjamin Hohl

13 Dec 2024

Chief Financial Officer

Exercised, kept

13,000

$2.48

$32.24K

Showing 250 of 414 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 327

Amendments (4/A) skipped 10

Filings about a different issuer 0

Unreadable filings 0

Joint filings 32

Sales on a Rule 10b5-1 plan 150

Sales straight out of an exercise 150

Sales at will 64

Transactions with no price 0

Shares from compensation/vesting 45,234,647

Sales filed before the plan box existed 44

History held since 16 Mar 2020